PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21361697-7 2011 Analysis of the trajectory lengths revealed two different binding durations with tau(1) = 77 +- 1 ms and tau(2) = 388 +- 11 ms. Agonistic stimulation of the beta(2)AR-Alexa-NA complexes with 1 muM terbutaline caused immobilization of almost 50% of the receptors within 35 min. Terbutaline 197-208 adrenoceptor beta 2 Homo sapiens 157-166 21329664-8 2011 Exposing Panc-1 cells to the beta2 adrenergic receptor agonist, terbutaline, increased the miR-132 and miR-212 expression by 2- to 4-fold. Terbutaline 64-75 adrenoceptor beta 2 Homo sapiens 29-54 21874331-1 2011 This study aims to investigate the association between prenatal exposure to terbutaline and other beta2 adrenergic receptor (B2AR) agonists and autism spectrum disorders (ASDs). Terbutaline 76-87 adrenoceptor beta 2 Homo sapiens 98-123 21874331-1 2011 This study aims to investigate the association between prenatal exposure to terbutaline and other beta2 adrenergic receptor (B2AR) agonists and autism spectrum disorders (ASDs). Terbutaline 76-87 adrenoceptor beta 2 Homo sapiens 125-129 19857486-7 2010 beta(2)-adrenoceptor agonists, salbutanol and terbutaline inhibited AGE-2- and AGE-3-induced adhesion expression and cytokine production, but alpha(1)-, alpha(2)- and beta(1)-adrenoceptor agonist had no effect, indicating that the stimulation of beta(2)-adrenoceptor might improve AGEs-initiated complications in diabetes. Terbutaline 46-57 adrenoceptor beta 2 Homo sapiens 246-266 21385652-6 2011 RESULTS: The polymorphisms of beta(2)-AR 27 but not 16 or 164 were significantly associated with the response to terbutaline nebulizer (p<0.05). Terbutaline 113-124 adrenoceptor beta 2 Homo sapiens 30-40 21385652-11 2011 CONCLUSION: These findings suggest that polymorphisms of beta(2)-AR 16 are related to nocturnal asthma and polymorphisms of beta(2)-AR 27 are associated with the variable responses to the inhaled terbutaline in children with nocturnal and nonnocturnal asthma. Terbutaline 196-207 adrenoceptor beta 2 Homo sapiens 57-67 21385652-11 2011 CONCLUSION: These findings suggest that polymorphisms of beta(2)-AR 16 are related to nocturnal asthma and polymorphisms of beta(2)-AR 27 are associated with the variable responses to the inhaled terbutaline in children with nocturnal and nonnocturnal asthma. Terbutaline 196-207 adrenoceptor beta 2 Homo sapiens 124-134 20519311-3 2010 We tested the hypothesis that ADRB2 gene variation would influence the SVR response to ADRB2 agonist terbutaline (Terb) during ganglionic blockade. Terbutaline 101-112 adrenoceptor beta 2 Homo sapiens 30-35 20519311-3 2010 We tested the hypothesis that ADRB2 gene variation would influence the SVR response to ADRB2 agonist terbutaline (Terb) during ganglionic blockade. Terbutaline 101-112 adrenoceptor beta 2 Homo sapiens 87-92 20519311-3 2010 We tested the hypothesis that ADRB2 gene variation would influence the SVR response to ADRB2 agonist terbutaline (Terb) during ganglionic blockade. Terbutaline 114-118 adrenoceptor beta 2 Homo sapiens 30-35 20519311-3 2010 We tested the hypothesis that ADRB2 gene variation would influence the SVR response to ADRB2 agonist terbutaline (Terb) during ganglionic blockade. Terbutaline 114-118 adrenoceptor beta 2 Homo sapiens 87-92 21385652-0 2011 Polymorphisms of the beta2-adrenergic receptor correlated to nocturnal asthma and the response of terbutaline nebulizer. Terbutaline 98-109 adrenoceptor beta 2 Homo sapiens 21-46 20837485-6 2010 A similar partial beta(2)AR activation signal was revealed for the synthetic agonists fenoterol and terbutaline. Terbutaline 100-111 adrenoceptor beta 2 Homo sapiens 18-27 20012638-1 2010 Terbutaline (Bricanyl) and its prodrug Bambuterol (Bambec) are highly potent beta(2)-adrenoceptor agonists often used in asthma patients. Terbutaline 0-11 adrenoceptor beta 2 Homo sapiens 77-97 20012638-1 2010 Terbutaline (Bricanyl) and its prodrug Bambuterol (Bambec) are highly potent beta(2)-adrenoceptor agonists often used in asthma patients. Terbutaline 13-21 adrenoceptor beta 2 Homo sapiens 77-97 19684287-5 2009 Two antagonists (propranolol, alprenolol) and 2 agonists (metaproterenol, terbutaline) for beta(2)AR were investigated in a displacement assay using europium(III)-labeled pindolol ligand. Terbutaline 74-85 adrenoceptor beta 2 Homo sapiens 91-100 17569809-4 2007 METHODS: Among 55 subjects, cardiac contractile response to the beta2-adrenergic receptor agonist terbutaline was assessed from the peak myocardial velocity of systolic shortening (Sm) in 18 subjects with the Ile-164 variant and 37 matched controls. Terbutaline 98-109 adrenoceptor beta 2 Homo sapiens 64-89 19462961-1 2009 Phenolic beta(2)-adrenoreceptor agonists salbutamol, fenoterol, and terbutaline relax smooth muscle cells that relieve acute airway bronchospasm associated with asthma. Terbutaline 68-79 adrenoceptor beta 2 Homo sapiens 9-31 16024912-5 2005 The Met/Met genotype was associated with a marked increase of 1.5 log units in the lipolytic sensitivity to the beta2-adrenoceptor agonist terbutaline (P=0.0008) as compared with the Thr/Thr and Thr/Met genotypes. Terbutaline 139-150 adrenoceptor beta 2 Homo sapiens 112-130 16448568-8 2006 Our data support the existence of differences between these six genotypes both in the shape of the dose response relationship of the beta2-adrenoceptor agonist fenoterol as well as in the propensity to develop tolerance for these effects by pre-treatment with terbutaline. Terbutaline 260-271 adrenoceptor beta 2 Homo sapiens 133-151 16417856-7 2005 Prenatal overstimulation of the beta2-adrenergic receptor by terbutaline or by increased signaling of genetic polymorphisms of the beta2-adrenergic receptor that have diminished desensitization can affect cellular responses and developmental programs in the fetal brain, leading to autism. Terbutaline 61-72 adrenoceptor beta 2 Homo sapiens 32-57 17211154-2 2007 The renal functional responses to the systemic injection of the beta2-AR agonist terbutaline in Wistar rats over-expressing renal beta2-AR were compared with those of nontreated rats. Terbutaline 81-92 adrenoceptor beta 2 Homo sapiens 64-72 17211154-2 2007 The renal functional responses to the systemic injection of the beta2-AR agonist terbutaline in Wistar rats over-expressing renal beta2-AR were compared with those of nontreated rats. Terbutaline 81-92 adrenoceptor beta 2 Homo sapiens 130-138 15998544-3 2005 The selective beta2-AR agonists salbutamol and terbutaline induced a similar inhibitory pattern of IL-18 and IL-12 production. Terbutaline 47-58 adrenoceptor beta 2 Homo sapiens 14-22 16153394-9 2005 Long-term terbutaline treatment desensitizes venous beta2-AR in a haplotype-dependent manner, with haplotype A (Arg16Gln27Thr164) showing greater desensitization than haplotype B (Gly16Gln27Thr164), which shows greater desensitization than haplotype C (Gly16Glu27Thr164). Terbutaline 10-21 adrenoceptor beta 2 Homo sapiens 52-60 15715182-4 2005 Traditional beta2-adrenoceptor agonists (beta2-agonists), such as salbutamol, terbutaline and fenoterol, were characterised by a rapid onset but relatively short duration of action. Terbutaline 78-89 adrenoceptor beta 2 Homo sapiens 12-30 15798957-0 2005 Influence of sex and beta2 adrenergic receptor haplotype on resting and terbutaline-stimulated whole body lipolysis. Terbutaline 72-83 adrenoceptor beta 2 Homo sapiens 21-46 15655528-6 2005 Those beta2-adrenoceptor agonists used clinically for the treatment of asthma and COPD were beta2 selective: 29-, 61- and 2818-fold for salbutamol, terbutaline and salmeterol over beta1, respectively. Terbutaline 148-159 adrenoceptor beta 2 Homo sapiens 6-24 15458278-3 2004 The selective beta2-AR agonists salbutamol and terbutaline induced a similar co-stimulatory molecule expression pattern. Terbutaline 47-58 adrenoceptor beta 2 Homo sapiens 14-22 15311061-4 2004 All beta2-adrenoceptor agonists tested (salbutamol, procaterol and terbutaline) attenuated the KCl induced contraction. Terbutaline 67-78 adrenoceptor beta 2 Homo sapiens 4-22 14745978-1 2003 BACKGROUND: Beta(2)-Adrenoceptor (betaAR) agonists, such as terbutaline, are widely used to arrest preterm labor. Terbutaline 60-71 adrenoceptor beta 2 Homo sapiens 12-32 15229461-0 2004 Modeling the metabolic effects of terbutaline in beta2-adrenergic receptor diplotypes. Terbutaline 34-45 adrenoceptor beta 2 Homo sapiens 49-74 15145612-3 2004 The selective beta 2-AR agonists, salbutamol and terbutaline, induced a similar pattern of cytokine production, indicating that the effect of these AR agonists on cytokine production was through beta 2-AR stimulation. Terbutaline 49-60 adrenoceptor beta 2 Homo sapiens 14-23 15145612-3 2004 The selective beta 2-AR agonists, salbutamol and terbutaline, induced a similar pattern of cytokine production, indicating that the effect of these AR agonists on cytokine production was through beta 2-AR stimulation. Terbutaline 49-60 adrenoceptor beta 2 Homo sapiens 195-204 14610225-1 2004 Beta(2)-adrenoceptor agonists, especially terbutaline, are widely used to arrest preterm labor, but they also cross the placenta to stimulate fetal beta-adrenoceptors that control neural cell differentiation. Terbutaline 42-53 adrenoceptor beta 2 Homo sapiens 0-20 14745978-1 2003 BACKGROUND: Beta(2)-Adrenoceptor (betaAR) agonists, such as terbutaline, are widely used to arrest preterm labor. Terbutaline 60-71 adrenoceptor beta 2 Homo sapiens 34-40 12966369-4 2003 In time-course studies, however, in groups A and C lymphocyte beta(2)AR showed significant (P <.05, repeated-measures ANOVA) down-regulation as early as 24 hours after the first terbutaline intake, whereas in group B significant (P <.05, repeated-measures ANOVA) beta(2)AR decreases were observed only 72 hours after the first terbutaline intake. Terbutaline 181-192 adrenoceptor beta 2 Homo sapiens 62-71 12966369-4 2003 In time-course studies, however, in groups A and C lymphocyte beta(2)AR showed significant (P <.05, repeated-measures ANOVA) down-regulation as early as 24 hours after the first terbutaline intake, whereas in group B significant (P <.05, repeated-measures ANOVA) beta(2)AR decreases were observed only 72 hours after the first terbutaline intake. Terbutaline 333-344 adrenoceptor beta 2 Homo sapiens 62-71 12826277-6 2003 Furthermore, Stx2-stimulated apoptosis, detected by TUNEL, annexin V and mitochondrial potential, was inhibited by terbutaline (P<0.05) which was prevented by cAMP-PKA inhibitors and a beta(2)-adrenoceptor antagonist. Terbutaline 115-126 adrenoceptor beta 2 Homo sapiens 188-208 12826277-8 2003 On the other hand, p38MAPK inhibition by terbutaline prevented Stx2-induced apoptosis and caspase activity through a cAMP-independent pathway via beta(2)-adrenoceptor. Terbutaline 41-52 adrenoceptor beta 2 Homo sapiens 146-166 12569076-1 2003 1 The principal aim of the present study was to determine whether long-term treatment of human lung mast cells (HLMC) with the clinically-relevant beta(2)-adrenoceptor agonists, salbutamol and terbutaline, leads to desensitization of beta(2)-adrenoceptor-mediated responses in these cells. Terbutaline 193-204 adrenoceptor beta 2 Homo sapiens 147-167 12759717-4 2003 Atropine enhanced HR-increasing effects of all three beta-AR agonists and exercise; increases were larger for beta2-AR (terbutaline, adrenaline) mediated effects than for beta1-AR (exercise) mediated effects. Terbutaline 120-131 adrenoceptor beta 2 Homo sapiens 110-118 12569076-1 2003 1 The principal aim of the present study was to determine whether long-term treatment of human lung mast cells (HLMC) with the clinically-relevant beta(2)-adrenoceptor agonists, salbutamol and terbutaline, leads to desensitization of beta(2)-adrenoceptor-mediated responses in these cells. Terbutaline 193-204 adrenoceptor beta 2 Homo sapiens 234-254 12569076-2 2003 2 The non-selective beta-adrenoceptor agonist, isoprenaline, and the selective beta(2)-adrenoceptor agonists, salbutamol and terbutaline, inhibited the IgE-mediated release of histamine from HLMC. Terbutaline 125-136 adrenoceptor beta 2 Homo sapiens 79-99 12538816-5 2003 beta 2-AR-selective agonists salbutanol and terbutaline down-regulated IL-18-induced ICAM-1 expression on monocytes, but alpha 1-, alpha 2-, or beta1-AR agonist had no effect. Terbutaline 44-55 adrenoceptor beta 2 Homo sapiens 0-9 12538816-6 2003 In the same manner, salbutanol and terbutaline as well as norepinephrine, epinephrine, and isoproterenol regulated the IL-18-induced cytokine production, including IL-12, tumor necrosis factor-alpha or interferon-gamma through the stimulation of beta 2-AR. Terbutaline 35-46 adrenoceptor beta 2 Homo sapiens 246-255 29492853-9 2002 The time-course of some of the cardiovascular effects of a SC dose of terbutaline in relation to terbutaline plasma concentrations was unexpected and suggests direct beta2-adrenoreceptor-mediated effects on the heart. Terbutaline 70-81 adrenoceptor beta 2 Homo sapiens 166-186 29492853-9 2002 The time-course of some of the cardiovascular effects of a SC dose of terbutaline in relation to terbutaline plasma concentrations was unexpected and suggests direct beta2-adrenoreceptor-mediated effects on the heart. Terbutaline 97-108 adrenoceptor beta 2 Homo sapiens 166-186 11429395-4 2001 The fat cells of Ile carriers displayed a 6 fold increase (P=0.02) in the lipolytic EC(50) of terbutaline (a selective beta(2)-adrenoceptor agonist), but no change in the lipolytic action of dobutamine (a selective beta(1)-adrenoceptor agonist), compared with the Thr carriers. Terbutaline 94-105 adrenoceptor beta 2 Homo sapiens 119-139 11675405-9 2001 Terbutaline (10(-6) M to 10(-8) M) suppressed MAPK (p42/p44, p38), NF-kappa B (p50, p65), and TNF-alpha promoter activity in a dose-dependent way that was prevented by the beta(2)-adrenoceptor antagonist, ICI118,551. Terbutaline 0-11 adrenoceptor beta 2 Homo sapiens 172-192 11675405-12 2001 In summary, the downregulation of TNF-alpha transcription by terbutaline was mediated by an inhibitory effect of beta(2)-adrenoceptor activation on MAPK (p42/p44, p38) and NF-kappa B (p50/p65), which were exerted through a cAMP-PKA pathway and a cAMP-independent mechanism. Terbutaline 61-72 adrenoceptor beta 2 Homo sapiens 113-133 14720033-1 2002 Beta2-adrenoceptor agonists (beta2-agonists) such as albuterol (salbutamol) and terbutaline and their long-acting analogs salmeterol and formoterol are widely used as bronchodilators in the treatment of asthma. Terbutaline 80-91 adrenoceptor beta 2 Homo sapiens 0-18 11256987-0 2001 beta2-Adrenoceptor desensitization in human alveolar macrophages induced by inhaled terbutaline in vivo is not counteracted by budesonide. Terbutaline 84-95 adrenoceptor beta 2 Homo sapiens 0-18 11325192-2 2001 Several purported agonists, including isoproterenol, epinephrine, norepinephine, dobutamine, salbutamol, and terbutaline, exhibited dual-affinity displacement curves, which is characteristic of agonist binding to betaAR. Terbutaline 109-120 adrenoceptor beta 2 Homo sapiens 213-219 10952688-2 2000 SR 59119A and SR 59104A and CGP 12177 (two selective agonists and a partial agonist, respectively, of the beta(3)-AR), salbutamol and terbutaline (beta(2)-AR agonists) each produced a concentration-dependent relaxation of the myometrial spontaneous contractions. Terbutaline 134-145 adrenoceptor beta 2 Homo sapiens 147-157 10226872-11 1999 Tremulousness observed during the first few days of terbutaline administration disappeared after 4 to 8 days, indicating development of desensitization of beta 2-adrenoceptor-mediated noncardiovascular responses. Terbutaline 52-63 adrenoceptor beta 2 Homo sapiens 155-174 10629458-9 2000 Terbutaline induced similar alterations in the type-1/type-2 cytokine balance compared with EPI, indicating that the beta(2)adrenergic receptor is involved in these cytokine alterations. Terbutaline 0-11 adrenoceptor beta 2 Homo sapiens 117-143 10226872-1 1999 In humans, prolonged administration of the beta 2-adrenoceptor agonist terbutaline leads to a desensitization of beta 2-adrenoceptor-mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug ketotifen. Terbutaline 71-82 adrenoceptor beta 2 Homo sapiens 43-62 10226872-1 1999 In humans, prolonged administration of the beta 2-adrenoceptor agonist terbutaline leads to a desensitization of beta 2-adrenoceptor-mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug ketotifen. Terbutaline 71-82 adrenoceptor beta 2 Homo sapiens 113-132 9843731-6 1998 beta2-Adrenoceptor stimulation with terbutaline induced a concentration-dependent increase in skeletal muscle glycerol levels and in tissue blood flow, whereas perfusion with beta1- or beta3-adrenoceptor agonists (dobutamine or CGP-12177) did not influence the glycerol concentration or blood flow. Terbutaline 36-47 adrenoceptor beta 2 Homo sapiens 0-18 10229127-3 1999 Expression of alpha1b- and alpha1d-AR mRNA can be obtained by culturing freshly isolated human peripheral blood monocytes with the neuroendocrine mediators dexamethasone or the beta2-AR agonist terbutaline. Terbutaline 194-205 adrenoceptor beta 2 Homo sapiens 177-185 8842454-14 1996 The beta 2-adrenoceptor agonist, terbutaline (1 mumol l-1) increased (1.53 [1.14-2.01]) and the beta-adrenoceptor antagonist, pindolol (1 mumol l-1) suppressed noradrenaline release (0.62 [0.49-0.79]) under normoxic conditions. Terbutaline 33-44 adrenoceptor beta 2 Homo sapiens 4-23 9876334-0 1998 Terbutaline-induced desensitization of human cardiac beta 2-adrenoceptor-mediated positive inotropic effects: attenuation by ketotifen. Terbutaline 0-11 adrenoceptor beta 2 Homo sapiens 53-72 9876334-4 1998 METHODS: We investigated, in a single blinded, randomised, placebo-controlled, cross-over study of ten healthy male volunteers (mean age, 25.3 +/- 0.7 years), the effects of two weeks treatment with the beta 2-adrenoceptor agonist terbutaline (3x5 mg/day p.o.) Terbutaline 231-242 adrenoceptor beta 2 Homo sapiens 203-222 8921745-0 1996 Interaction of beta 2-adrenoceptor agonists with native cyclodextrins: application to the development of chiral assays for terbutaline. Terbutaline 123-134 adrenoceptor beta 2 Homo sapiens 15-34 9373782-4 1997 We assessed the effects of 2 weeks treatment with the beta 2-adrenoceptor agonist terbutaline (3 x 5 mg day-1 p.o.) Terbutaline 82-93 adrenoceptor beta 2 Homo sapiens 54-73 8144793-0 1994 Positive inotropic effects of the beta 2-adrenoceptor agonist terbutaline in the human heart: effects of long-term beta 1-adrenoceptor antagonist treatment. Terbutaline 62-73 adrenoceptor beta 2 Homo sapiens 34-53 8751019-1 1995 Changes in beta 2-adrenoceptor function by chronic dosing of beta 2-mimetics and the possible influence of a single dose of prednisone have been studied as changes over time in the concentration-effect relationship of the beta 2-adrenoceptor agonist terbutaline. Terbutaline 250-261 adrenoceptor beta 2 Homo sapiens 11-30 8751019-1 1995 Changes in beta 2-adrenoceptor function by chronic dosing of beta 2-mimetics and the possible influence of a single dose of prednisone have been studied as changes over time in the concentration-effect relationship of the beta 2-adrenoceptor agonist terbutaline. Terbutaline 250-261 adrenoceptor beta 2 Homo sapiens 222-241 8751145-0 1995 Factors behind the functional beta 2-adrenoceptor selectivity of terbutaline. Terbutaline 65-76 adrenoceptor beta 2 Homo sapiens 30-49 8764303-1 1996 Infusion of the beta 2-adrenoceptor agonist terbutaline will cause an activation of the Na(+)-K+ pump that leads to lowering of plasma K+ concentration and intracellular Na+ concentration. Terbutaline 44-55 adrenoceptor beta 2 Homo sapiens 16-35 7889286-8 1994 The duration of beta-adrenoceptor blockade was tested by determining the adenosine 3",5"-cyclic monophosphate (cyclic AMP) production induced by terbutaline (a beta 2-adrenoceptor specific agonist). Terbutaline 145-156 adrenoceptor beta 2 Homo sapiens 160-179 8144793-6 1994 Terbutaline effects were antagonized only by the beta 2-adrenoceptor antagonist ICI 118,551, indicating that they were mediated by beta 2-adrenoceptor stimulation. Terbutaline 0-11 adrenoceptor beta 2 Homo sapiens 49-68 8144793-6 1994 Terbutaline effects were antagonized only by the beta 2-adrenoceptor antagonist ICI 118,551, indicating that they were mediated by beta 2-adrenoceptor stimulation. Terbutaline 0-11 adrenoceptor beta 2 Homo sapiens 131-150 1280742-2 1992 To find out whether such "cross-regulation" between Gs protein- and Gi protein-coupled receptors can be also demonstrated in vivo in humans, we studied the effects of a 2 week treatment of eight male volunteers with the beta 2-adrenoceptor agonist terbutaline (3 x 5 mg/day) on beta 2-adrenoceptor density and Gi-protein content in lymphocytes and on alpha 2-adrenoceptor density (Gi-coupled receptors) in platelets. Terbutaline 248-259 adrenoceptor beta 2 Homo sapiens 220-239 8392360-2 1993 A double-blind placebo-controlled study was conducted on the effects of oral terbutaline (beta 2-adrenoceptor agonist) and propranolol (beta 1 beta 2-adrenoceptor antagonist) on basal heat production of skeletal muscle, measured ex vivo by direct microcalorimetry. Terbutaline 77-88 adrenoceptor beta 2 Homo sapiens 90-109 1279289-0 1992 Terbutaline-induced desensitization of beta 2-adrenoceptor in vivo function in humans: attenuation by ketotifen. Terbutaline 0-11 adrenoceptor beta 2 Homo sapiens 39-58 1279289-5 1992 These parameters were assessed before and after a 14-day treatment with the beta 2-adrenoceptor agonist terbutaline (5 mg three times daily) with or without simultaneous administration of ketotifen (1 mg twice daily). Terbutaline 104-115 adrenoceptor beta 2 Homo sapiens 76-95 1279289-6 1992 Terbutaline desensitized all in vivo effects involving beta 2-adrenoceptors (ISO-induced decrease in DBP and increase in plasma NE and, to a minor extent, the mixed beta 1- and beta 2-adrenoceptor-mediated increase in HR), but did not affect beta 1-adrenoceptor-mediated in vivo effects; concomitant treatment of the volunteers with ketotifen markedly blunted terbutaline-induced desensitization of beta 2-adrenoceptor in vivo function. Terbutaline 0-11 adrenoceptor beta 2 Homo sapiens 55-74 1279289-6 1992 Terbutaline desensitized all in vivo effects involving beta 2-adrenoceptors (ISO-induced decrease in DBP and increase in plasma NE and, to a minor extent, the mixed beta 1- and beta 2-adrenoceptor-mediated increase in HR), but did not affect beta 1-adrenoceptor-mediated in vivo effects; concomitant treatment of the volunteers with ketotifen markedly blunted terbutaline-induced desensitization of beta 2-adrenoceptor in vivo function. Terbutaline 360-371 adrenoceptor beta 2 Homo sapiens 55-74 1323000-5 1992 On the other hand, terbutaline sulfate, a full agonist to beta 2-AR, increased delta Vcfc partially in comparison with isoproterenol; 51% in NYHA I, 52% in NYHA II, 36% in NYHA III and 17% in NYHA IV. Terbutaline 19-38 adrenoceptor beta 2 Homo sapiens 58-67 8403793-8 1993 Sensitivity to terbutaline, a selective beta 2-adrenoceptor agonist, increased 25-fold (P = 0.01), whereas the ED50 values for dobutamine, a selective beta 1-adrenoceptor agonist, did not change significantly. Terbutaline 15-26 adrenoceptor beta 2 Homo sapiens 40-59 8383517-6 1993 Terbutaline infusion induced a significant rise in plasma glucose and a fall in plasma potassium in keeping with its beta 2-adrenoceptor stimulant properties. Terbutaline 0-11 adrenoceptor beta 2 Homo sapiens 117-136 8157045-1 1993 A double blind placebo-controlled study was conducted of the effects of oral propranolol (beta 1 beta 2-adrenoceptor antagonist) and terbutaline (beta 2-adrenoceptor agonist) on erythrocyte heat production, measured by direct microcalorimetry under static conditions at 37 degrees C and pH 7.4. Terbutaline 133-144 adrenoceptor beta 2 Homo sapiens 146-165 1349493-8 1992 beta 2-adrenoceptor antagonism was shown by attenuation of terbutaline induced hypokalaemic, chronotropic and finger tremor responses. Terbutaline 59-70 adrenoceptor beta 2 Homo sapiens 0-19 1541141-1 1992 The purpose of the study was to investigate whether a constant submaximal exercise challenge affected the plasma pharmacokinetics of an inhaled beta 2-adrenoceptor agonist, terbutaline sulfate. Terbutaline 173-192 adrenoceptor beta 2 Homo sapiens 144-163 1280742-3 1992 Terbutaline decreased the lymphocyte beta 2-adrenoceptor density by about 30%, but had no significant influence on lymphocyte Gi-protein levels (assessed by pertussis toxin-catalyzed [32P]ADP ribosylation) or on platelet alpha 2-adrenoceptor density. Terbutaline 0-11 adrenoceptor beta 2 Homo sapiens 37-56 1331993-1 1992 This pilot study was undertaken to characterize age-related alterations in airway and metabolic beta 2-adrenergic receptor response using terbutaline as a probe. Terbutaline 138-149 adrenoceptor beta 2 Homo sapiens 96-122 34592235-1 2021 Terbutaline sulphate (TS) is a selective short-acting beta2 adrenoceptor agonist used for asthma treatment. Terbutaline 0-20 adrenoceptor beta 2 Homo sapiens 54-72 1591462-4 1992 Beta 2-adrenoceptor mediated changes of plasma potassium and FEV1 were related to plasma concentrations of terbutaline and racemic metoprolol. Terbutaline 107-118 adrenoceptor beta 2 Homo sapiens 0-19 1973910-11 1990 Human lung tissue is found to be less susceptible than human MNL for beta 2-adrenoceptor down-regulation by terbutaline treatment at therapeutic doses. Terbutaline 108-119 adrenoceptor beta 2 Homo sapiens 69-88 34592235-1 2021 Terbutaline sulphate (TS) is a selective short-acting beta2 adrenoceptor agonist used for asthma treatment. Terbutaline 22-24 adrenoceptor beta 2 Homo sapiens 54-72 34909668-3 2021 Therefore, we sought to discover the effects of the beta2-adrenergic receptor agonist terbutaline on metabolism and protein synthesis in human primary skeletal muscle cells. Terbutaline 86-97 adrenoceptor beta 2 Homo sapiens 52-77 3169216-1 1988 In order to localize the main site of action of the beta 2-adrenoceptor selective agonist terbutaline and the beta 1-adrenoceptor selective antagonist atenolol in the airways of asthmatic patients, we compared the effects of these drugs on maximal expiratory flow-volume (MEFV) curves when breathing air and when breathing a helium-oxygen (HeO2) mixture. Terbutaline 90-101 adrenoceptor beta 2 Homo sapiens 52-71 2779705-1 1989 A case of rhabdomyolysis-induced acute renal failure secondary to overdosage with the beta 2-adrenoceptor agonist terbutaline is described. Terbutaline 114-125 adrenoceptor beta 2 Homo sapiens 86-105 2593433-2 1989 Terbutaline and clenbuterol, which are both selective beta 2-adrenoceptor agonists, produced a concentration-dependent decrease in contractile force of in vitro rabbit detrusor and proximal urethral smooth muscle. Terbutaline 0-11 adrenoceptor beta 2 Homo sapiens 54-73 2565392-1 1989 We studied the competitive interaction of terbutaline and two beta blockers, metoprolol and oxprenolol, with different cardioselectivity for the beta-2 adrenoceptor. Terbutaline 42-53 adrenoceptor beta 2 Homo sapiens 145-164 2577692-5 1989 Increased activation of beta 2-adrenoceptors by terbutaline infusion resulted in increased FEV1 and FVC as well as beta 2-adrenoceptor mediated reflex tachycardia and skeletal muscle tremor. Terbutaline 48-59 adrenoceptor beta 2 Homo sapiens 24-43 3410234-0 1988 Effect of terbutaline, a beta 2-adrenoreceptor agonist, on gastric acid secretion and serum gastrin concentrations in humans. Terbutaline 10-21 adrenoceptor beta 2 Homo sapiens 25-46 3410234-1 1988 Because beta-adrenoreceptor agonists inhibit gastrin-stimulated gastric acid secretion in animals, we postulated that the beta 2-adrenoreceptor agonist, terbutaline, would inhibit pentagastrin-stimulated acid secretion in humans. Terbutaline 153-164 adrenoceptor beta 2 Homo sapiens 122-143 2902621-1 1988 Terbutaline, a selective beta 2-adrenoreceptor agonist, has recently been advocated as a potential agent for treating patients with pancreatic fistulae. Terbutaline 0-11 adrenoceptor beta 2 Homo sapiens 25-46 2878680-5 1986 Bronchospasm induced by atenolol 50 mg and xamoterol 200 mg was completely reversed by inhalation of the beta 2-adrenoceptor agonist terbutaline to a cumulative dose of 4.0 mg. Terbutaline 133-144 adrenoceptor beta 2 Homo sapiens 105-124 22823-2 1977 Terbutaline, a selective beta2-adrenoceptor agonist, gave at a certain dose a more pronounced chronotropic than inotropic response, while a new beta1-selective adrenoceptor agonist (-)-H 80/62 produced the same degree of chronotropic and inotropic stimulation. Terbutaline 0-11 adrenoceptor beta 2 Homo sapiens 25-43 3030608-2 1986 To study the mechanism behind this increase, plasma insulin, plasma C-peptide, and blood glucose responses to the beta 2-adrenoceptor agonist terbutaline were investigated in healthy humans. Terbutaline 142-153 adrenoceptor beta 2 Homo sapiens 114-133 2869574-9 1985 Since terbutaline inhibits sigmoid and rectal motility in man during rectal distention, it is suggested that the inhibitory effect of beta-2-adrenoceptor agonists may be dependent on the mode of background stimulation of the colon. Terbutaline 6-17 adrenoceptor beta 2 Homo sapiens 134-153 2906082-4 1985 The studies described herein extend these findings to the conjunctiva, where the relatively selective beta 2-adrenoceptor agonists salbutamol and terbutaline reduced the microvascular permeability response to histamine. Terbutaline 146-157 adrenoceptor beta 2 Homo sapiens 102-121 6146956-4 1984 Isoprenaline, known to be a beta-adrenoceptor agonist with some alpha-adrenoceptor activity, had stimulatory and inhibitory effects, whereas the beta 2-adrenoceptor agonist, terbutaline, exhibited a pure inhibitory action. Terbutaline 174-185 adrenoceptor beta 2 Homo sapiens 145-164 6205605-0 1984 Sustained inhibition of antigen-induced histamine release from human lung by the beta 2-adrenoceptor agonist terbutaline. Terbutaline 109-120 adrenoceptor beta 2 Homo sapiens 81-100 6205605-1 1984 Antigen-induced histamine release from passively sensitized human lung tissue was inhibited in the presence of the beta 2-adrenoceptor agonist, terbutaline. Terbutaline 144-155 adrenoceptor beta 2 Homo sapiens 115-134 161461-1 1979 The acute bronchodilator effect of the beta 2-adrenoceptor agonist terbutaline was tested single-blind cross-over in out-patients with chronic obstructive airways disease (intrinsic asthma). Terbutaline 67-78 adrenoceptor beta 2 Homo sapiens 39-58 645781-1 1978 Terbutaline, a selective beta-2 adrenergic receptor stimulator, has been used to decrease myometrial activity and improve uteroplacental blood flow in 15 patients with acute intrapartum fetal distress. Terbutaline 0-11 adrenoceptor beta 2 Homo sapiens 25-51 4042527-4 1985 A dose-response curve was then plotted after inhalation of the beta 2-adrenoceptor agonist terbutaline. Terbutaline 91-102 adrenoceptor beta 2 Homo sapiens 63-82 2995446-3 1985 Terbutaline (3 X 5 mg/d) decreased lymphocyte beta 2-adrenoceptor density by approximately 40-50%; concomitantly, lymphocyte cAMP responses to 10 microM (-)-isoprenaline were significantly reduced. Terbutaline 0-11 adrenoceptor beta 2 Homo sapiens 46-65 2995446-4 1985 After withdrawal of terbutaline beta 2-adrenoceptor, density and responsiveness gradually increased, reaching predrug levels after 4 d. Prednisone (1 X 100 mg orally) accelerated beta 2-adrenoceptor recovery; only 8-10 h after administration of the steroid beta 2-adrenoceptor density and cAMP responses to (-)-isoprenaline had reached values not significantly different from pretreatment levels. Terbutaline 20-31 adrenoceptor beta 2 Homo sapiens 32-51 2995446-6 1985 Furthermore, ketotifen simultaneously applied with terbutaline completely prevented terbutaline-induced decrease in lymphocyte beta 2-adrenoceptor density and responsiveness. Terbutaline 51-62 adrenoceptor beta 2 Homo sapiens 127-146 2995446-6 1985 Furthermore, ketotifen simultaneously applied with terbutaline completely prevented terbutaline-induced decrease in lymphocyte beta 2-adrenoceptor density and responsiveness. Terbutaline 84-95 adrenoceptor beta 2 Homo sapiens 127-146 2412749-2 1985 The beta 2-adrenoceptor agonist terbutaline (125 micrograms IV) induced prompt IRI and C-peptide responses in hyperthyroid patients. Terbutaline 32-43 adrenoceptor beta 2 Homo sapiens 4-23 517068-1 1979 The acute bronchodilator effect of the beta 2-adrenoceptor agonist terbutaline was tested single-blind cross-over in out-patients with chronic obstructive airways disease (intrinsic asthma). Terbutaline 67-78 adrenoceptor beta 2 Homo sapiens 39-58 31371988-8 2019 In vitro, the activation of beta2-AR by terbutaline in M2-polarized macrophages elevated the proliferative, migratory and invasive attributes of HCC cells. Terbutaline 40-51 adrenoceptor beta 2 Homo sapiens 28-36 810302-0 1975 Evaluation of a new beta2 adrenergic receptor stimulant, terbutaline, in bronchospasm. Terbutaline 57-68 adrenoceptor beta 2 Homo sapiens 20-45 239414-0 1975 Evaluation of a new oral beta2-adrenoceptor stimulant bronchodilator, terbutaline. Terbutaline 70-81 adrenoceptor beta 2 Homo sapiens 25-43 31015039-0 2019 Contrasting photoreactivity of beta2-adrenoceptor agonists Salbutamol and Terbutaline in the presence of humic substances. Terbutaline 74-85 adrenoceptor beta 2 Homo sapiens 31-49 26002106-3 2015 The results of the zonal elution showed that clorprenaline, clenbuterol, methoxyphenamine, salbutamol, terbutaline, tulobuterol and bambuterol have only one type of binding site on immobilised beta2-AR, while nonlinear chromatography confirmed the existence of at least two types of binding sites between beta2-AR and clorprenaline, clenbuterol and bambuterol. Terbutaline 103-114 adrenoceptor beta 2 Homo sapiens 193-201 29883116-3 2018 Using adsorption energy distribution (AED) calculations, we achieved the best adsorption models for the binding of salbutamol, terbutaline, and pseudoephedrine to immobilized beta2-AR. Terbutaline 127-138 adrenoceptor beta 2 Homo sapiens 175-183 29883116-4 2018 The Langmuir model proved to be desirable for describing the adsorptions of salbutamol and terbutaline on immobilized beta2-AR, while the bi-Langmuir model was favorable to characterize the adsorption of pseudoephedrine on the receptor. Terbutaline 91-102 adrenoceptor beta 2 Homo sapiens 118-126 28719816-0 2017 Sulfate radical induced degradation of beta2-adrenoceptor agonists salbutamol and terbutaline: Phenoxyl radical dependent mechanisms. Terbutaline 82-93 adrenoceptor beta 2 Homo sapiens 39-57 28719816-1 2017 The present study investigated the reactivity and oxidation mechanisms of salbutamol (SAL) and terbutaline (TBL), two typical beta2-adrenoceptor agonists, towards sulfate radical (SO4-) by using photo-activated persulfate (PS). Terbutaline 95-106 adrenoceptor beta 2 Homo sapiens 126-144 28719816-1 2017 The present study investigated the reactivity and oxidation mechanisms of salbutamol (SAL) and terbutaline (TBL), two typical beta2-adrenoceptor agonists, towards sulfate radical (SO4-) by using photo-activated persulfate (PS). Terbutaline 108-111 adrenoceptor beta 2 Homo sapiens 126-144 28710773-0 2017 Reciprocal modulation of helper Th1 and Th17 cells by the beta2-adrenergic receptor agonist drug terbutaline. Terbutaline 97-108 adrenoceptor beta 2 Homo sapiens 58-83 26002106-3 2015 The results of the zonal elution showed that clorprenaline, clenbuterol, methoxyphenamine, salbutamol, terbutaline, tulobuterol and bambuterol have only one type of binding site on immobilised beta2-AR, while nonlinear chromatography confirmed the existence of at least two types of binding sites between beta2-AR and clorprenaline, clenbuterol and bambuterol. Terbutaline 103-114 adrenoceptor beta 2 Homo sapiens 305-313 23505234-11 2014 alpha- And beta-adrenergic agonists show no influence on expression levels of IL-7R on activated B cells; however, intracellular IL-7R downstream signalling is abrogated via the beta2-adreonceptor (beta2AR) agonist terbutaline. Terbutaline 215-226 adrenoceptor beta 2 Homo sapiens 178-196 24633512-3 2014 Using His-tagged beta2-adrenoceptor (beta2-AR) as a probe, we developed a new mathematical model to elucidate the interactions between the receptor and five ligands (methoxyphenamine, terbutaline, salbutamol, tulobuterol and fenoterol). Terbutaline 184-195 adrenoceptor beta 2 Homo sapiens 17-35 23505234-11 2014 alpha- And beta-adrenergic agonists show no influence on expression levels of IL-7R on activated B cells; however, intracellular IL-7R downstream signalling is abrogated via the beta2-adreonceptor (beta2AR) agonist terbutaline. Terbutaline 215-226 adrenoceptor beta 2 Homo sapiens 198-205 24088990-4 2013 Furthermore, we tested the hypothesis that the beta2 adrenoreceptor agonist terbutaline or its downstream effector cyclic adenosine monophosphate (cAMP) mitigates LPS-evoked changes of AQP expression. Terbutaline 76-87 adrenoceptor beta 2 Homo sapiens 47-67 24088990-13 2013 Thus, AQP1 and AQP5 expression is differentially regulated following exposure to LPS, the beta2 adrenoreceptor agonist terbutaline, and cAMP. Terbutaline 119-130 adrenoceptor beta 2 Homo sapiens 90-110